Live feed07:00:00·364dPRReleasevia QuantisnowSenti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid LeukemiaByQuantisnow·Wall Street's wire, on your screen.SNTI· Senti Biosciences Inc.Health Care
